Merit Medical Systems - MMSI Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merit Medical Systems in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MMSI shares.
View MMSI analyst ratings or view top-rated stocks.

6 equities research analysts have issued twelve-month target prices for Merit Medical Systems' shares. Their MMSI share price forecasts range from $69.00 to $78.00. On average, they anticipate the company's stock price to reach $72.14 in the next year. This suggests a possible upside of 21.2% from the stock's current price.
View analysts price targets for MMSI or view top-rated stocks among Wall Street analysts.

Merit Medical Systems' stock was trading at $62.30 at the beginning of the year. Since then, MMSI stock has decreased by 4.4% and is now trading at $59.54.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our MMSI earnings forecast.

Merit Medical Systems, Inc. (NASDAQ:MMSI) issued its earnings results on Wednesday, July, 27th. The medical instruments supplier reported $0.73 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.15. The medical instruments supplier had revenue of $294.98 million for the quarter, compared to analyst estimates of $280.55 million. Merit Medical Systems had a net margin of 5.24% and a trailing twelve-month return on equity of 13.74%. The firm's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.62 EPS.

Merit Medical Systems issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $2.42-$2.52 for the period, compared to the consensus EPS estimate of $2.48. The company issued revenue guidance of $1.12 billion-$1.14 billion, compared to the consensus revenue estimate of $1.13 billion.

158 employees have rated Merit Medical Systems Chief Executive Officer Fred P. Lampropoulos on Glassdoor.com. Fred P. Lampropoulos has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merit Medical Systems investors own include Citigroup (C), OraSure Technologies (OSUR), LightPath Technologies (LPTH), Overstock.com (OSTK), EXFO (EXFO), Energy Transfer (ET), RTI Surgical (RTIX), NVIDIA (NVDA), Under Armour (UA) and Advanced Micro Devices (AMD).

Merit Medical Systems trades on the NASDAQ under the ticker symbol "MMSI."

Shares of MMSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MMSI stock can currently be purchased for approximately $59.54.

Merit Medical Systems (NASDAQ:MMSI) has a market capitalization of $3.38 billion and generates $1.07 billion in revenue each year. The medical instruments supplier earns $48.45 million in net income (profit) each year or $1.02 on an earnings per share basis.

The company employs 6,446 workers across the globe.

Merit Medical Systems' mailing address is 1600 WEST MERIT PARK WAY, SOUTH JORDAN UT, 84095. The official website for the company is www.merit.com. The medical instruments supplier can be reached via phone at (801) 253-1600, via email at awright@merit.com, or via fax at 801-253-1652.